SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-22-021977
Filing Date
2022-08-11
Accepted
2022-08-11 09:05:50
Documents
18
Period of Report
2022-08-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 43227
2 ex99-1.htm EX-99.1 66383
3 ex99-1_005.jpg GRAPHIC 2448
4 ex99-1_001.jpg GRAPHIC 96620
5 ex99-1_002.jpg GRAPHIC 61178
6 ex99-1_003.jpg GRAPHIC 101346
7 ex99-1_004.jpg GRAPHIC 23497
  Complete submission text file 0001493152-22-021977.txt   688265

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE prph-20220811.xsd EX-101.SCH 2971
9 XBRL LABEL FILE prph-20220811_lab.xml EX-101.LAB 34240
10 XBRL PRESENTATION FILE prph-20220811_pre.xml EX-101.PRE 22367
12 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3691
Mailing Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530
Business Address 711 STEWART AVE, SUITE 200 GARDEN CITY NEW YORK NY 11530 (215) 345-0919
ProPhase Labs, Inc. (Filer) CIK: 0000868278 (see all company filings)

IRS No.: 232577138 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21617 | Film No.: 221153929
SIC: 2834 Pharmaceutical Preparations